Antidepressants for polycystic ovary syndrome

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 5, 2013, Pages

  Zhuang, Jing ^a   Wang, Xianding ^b   Xu, Liangzhi ^c   Wu, Taixiang ^b   Kang, Deying ^b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIOBESITY AGENT; FLUOXETINE; METFORMIN; ORAL CONTRACEPTIVE AGENT; PLACEBO; SIBUTRAMINE; CYCLOBUTANE DERIVATIVE;

ANOVULATION; CLINICAL OUTCOME; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MOOD DISORDER; OBESITY; OVARY INSUFFICIENCY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT RESPONSE; FEMALE; PSYCHOLOGICAL ASPECT; PSYCHOLOGY;

ANTIDEPRESSIVE AGENTS; CYCLOBUTANES; DEPRESSION; FEMALE; FLUOXETINE; HUMANS; POLYCYSTIC OVARY SYNDROME; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84891685582     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008575.pub2     Document Type: Review

References (54)

1. Karabacak IY, Karabacak O, Toruner FB, Akdemir O, Arslan M. Treatment effect of sibutramine compared to fluoxetine on leptin levels in polycystic ovary disease. Gynecological Endocrinology 2004;19(4):196-201. [DOI: 10.1080/09513590400012077].
2. Amer SA, Li TC, Metwally M, Emarh M, Ledger WL. Randomized controlled trial comparing laparoscopic ovarian diathermy with clomiphene citrate as a first-line method of ovulation induction in women with polycystic ovary syndrome. Human Reproduction 2009;24(1):219-25.
3. Florakis D, Diamanti-Kandarakis E, Katsikis I, Nassis GP, Karkanaki A, Georgopoulos N, et al.Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. International Journal of Obesity 2008;32(4):692-9. [DOI: 10.1038/sj.ijo.0803777].
4. Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ, et al.Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010;375(9712):385-95.
5. Hirschberg A. Polycystic ovary syndrome, obesity and reproductive implications. Womens Health 2009;5(5):529-40.
6. Lazurova I, Dravecka I, Kraus V, Petrovicova J. Metformin versus sibutramine in the treatment of hyperinsulinemia in chronically anovulating women. Bratisl Lek Listy 2004;105(5-6):207-10.
7. Lindholm A, Bixo M, Bjorn I, Wolner-Hanssen P, Eliasson M, Larsson A, et al.Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomised, double-blind, placebo-controlled trial. Fertility and Sterility 2008;89:1221-8. [DOI: 10.1016/j.fertnstert.2007.05.002].
8. Mansson M, Holte J, Landin-Wilhelmsen K, Dahlgren E, Johansson A, Landen M. Women with polycystic ovary syndrome are often depressed or anxious - a case control study. Psychoneuroendocrinology 2008;33(8):1132-8. [DOI: 10.1016/j.psyneuen.2008.06.003].
9. Sabuncu T, Harma M, Harma M, Nazligul Y, Kilic F. Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. Fertility and Sterility 2003;80(5):1199-204. [DOI: 10.1016/S0015-0282(03)02162-9].
10. Shi X, Zhang L, Fu S. Psychiatric symptoms and monoamine neurotransmitter in serum of PCOS with infertility patients. Chinese Journal of Clinical Psychology 2008;16(3):294-6.
11. Tziomalos K, Dimitroula HV, Katsiki N, Savopoulos C, Hatzitolios AI. Effects of lifestyle measures, antiobesity agents, and bariatric surgery on serological markers of inflammation in obese patients. Mediators of inflammation 2010;2010:364957.
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th Edition. Washington DC: American Psychiatric Association, 1994.
13. Balen AH, Rutherford AJ. Managing anovulatory infertility and polycystic ovary syndrome. BMJ 2007;335:663-9.
14. Barnard L, Ferriday D, Guenther N, Strauss B, Balen AH, Dye L. Quality of life and psychological well being in polycystic ovary syndrome. Human Reproduction 2007;22(8):2279-86.
15. Benson S, Hahn S, Tan S, Mann K, Janssen OE, Schedlowski M, et al.Prevalence and implications of anxiety in polycystic ovary syndrome: results of an internet-based survey in Germany. Human Reproduction 2009;24(6):1446-51.
16. Bideci A, Camurdan MO, Yesilkaya E, Demirel F, Cinaz P. Serum ghrelin, leptin and resistin levels in adolescent girls with polycystic ovary syndrome. The Journal of Obstetrics and Gynaecology Research 2008;34:578-84.
17. Boomsma CM, Fauser BC, Macklon NS. Pregnancy complications in women with polycystic ovary syndrome. Seminars in Reproductive Medicine 2008;26:72-84.
18. Ching HL, Burke V, Stuckey BG. Quality of life and psychological morbidity in women with polycystic ovary syndrome: body mass index, age and the provision of patient information are significant modifiers. Clinical Endocrinology 2007;66(3):373-9.
19. Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reproductive Biomedicine Online 2009;19:398-405.
20. Dasgupta S, Reddy BM. Present status of understanding on the genetic etiology of polycystic ovary syndrome. Journal of Postgraduate Medicine 2008;54:115-25.
21. Diamanti-Kandarakis E, Piperi C. Genetics of polycystic ovary syndrome: searching for the way out of the labyrinth. Human Reproduction Update 2005;11:631-43.
22. Epling J, Family Practice Inquiries Network. Is fluoxetine an effective therapy for weight loss in obese patients?. American Family Physician 2003;68(12):2437-8.
23. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Human Reproduction 2004;19:41-7.
24. The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Human Reproduction 2008;23:462-77.
25. Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. International Journal of Obesity and Related Metabolic Disorders 2002;26(2):262-73.
26. Halford JC, Harrold JA, Lawton CL, Blundell JE. Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. Current Drug Targets 2005;6(2):201-13.
27. Halpern A, Mancini MC. Treatment of obesity: an update on anti-obesity medications. Obesity Reviews 2003;4(1):25-42.
28. Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Practice & Research. Clinical Obstetrics & Gynaecology 2004;18:671-83.
29. Herbert D, Lucke J, Dobson A. Depression: an emotional obstacle to seeking medical advice for infertility. Fertility and Sterility 2010;94(5):1817-21.
30. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-60.
31. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of interventions 5.1.0 [updated March 2011].. The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org.
32. Himelein MJ, Thatcher SS. Polycystic ovary syndrome and mental health: a review. Obstetrical & Gynecological Survey 2006;61(11):723-32.
33. Hollinrake E, Abreu A, Maifeld M, Van Voorhis BJ, Dokras A. Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertility and Sterility 2007;87(6):1369-76.
34. Jedel E, Waern M, Gustafson D, Landen M, Eriksson E, Holm G, et al.Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index. Human Reproduction 2010;25(2):450-6.
35. Kerchner A, Lester W, Stuart SP, Dokras A. Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study. Fertility and Sterility 2009;91(1):207-12.
36. Lobo RA. Priorities in polycystic ovary syndrome. The Medical Journal of Australia 2001;174:554-5.
37. Meyer C, McGrath BP, Teede HJ. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. The Journal of Clinical Endocrinology and Metabolism 2005;90:5711-6.
38. McCook JG, Reame NE, Thatcher SS. Health-related quality of life issues in women with polycystic ovary syndrome. Journal of Obstetric, Gynecologic, and Neonatal Nursing 2005;34(1):12-20.
39. McElroy SL, Guerdjikova AI, Martens B, Keck PE Jr, Pope HG, Hudson JI. Role of antiepileptic drugs in the management of eating disorders. CNS Drugs 2009;23:139-56.
40. Nestler JE. Insulin regulation of human ovarian androgens. Human Reproduction 1997;12:53-62.
41. Padmanabhan V. Polycystic ovary syndrome "A riddle wrapped in a mystery inside an enigma". The Journal of Clinical Endocrinology and Metabolism 2009;94:1883-5.
42. Peritogiannis V, Goulia P, Pappas D, Hyphantis T, Mavreas V. Amenorrhea after sertraline introduction in an amisulpride-treated patient with undiagnosed polycystic ovary disease. Journal of Clinical Psychopharmacology 2007;27:235-7.
43. Psychiatric Institute of the Chinese Medical Association. Chinese Classification of Mental Disorders. Nan Jing: Chinese Medical Association 1995; Vol. 3.
44. Rasgon NL, Rao RC, Hwang S, Altshuler LL, Elman S, Zuckerbrow-Miller J, et al.Depression in women with polycystic ovary syndrome: clinical and biochemical correlates. Journal of Affective Disorders 2003;74(3):299-304.
45. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
46. Shumak SL. Even lean women with PCOS are insulin resistant. BMJ 2009;338:b954.
47. Tara MW, Jonathan CL, David RM. Use and abuse of HOMA modeling. Diabetes Care 2004;27(6):1485-95.
48. Tong X, Tong E. The history and development of antidepressants. Herald of Medicine 2009;28(2):135-9.
49. Tziomalos K, Krassas GE, Tzotzas T. The use of sibutramine in the management of obesity and related disorders: an update. Vascular Health & Risk Management 2009;5:441-52.
50. Veldhuis JD, Pincus SM, Garcia-Rudaz MC, Ropelato MG, Escobar ME, Barontini M. Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome. The Journal of Clinical Endocrinology and Metabolism 2001;86:3772-8.
51. Vrbikova J, Hainer V. Obesity and polycystic ovary syndrome. Obesity Facts 2009;2(1):26-35.
52. World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization 1992.
53. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organization Technical Report Service 2000;894:i-xii, 1-253.
54. Zwirska-Korczala K, Sodowski K, Konturek SJ, Kuka D, Kukla M, Brzozowski T, et al.Postprandial response of ghrelin and PYY and indices of low-grade chronic inflammation in lean young women with polycystic ovary syndrome. Journal of Physiology and Pharmacology 2008;59:161-78.